**ÀϽÃ: 2015.5.16(Åä)
**Àå¼Ò: ÆĶó´ÙÀ̽ºÈ£ÅÚ ºÎ»ê
5/16(Åä) | Grand Ballroom 1 | Grand Ballroom 2 | Grand Ballroom 3 | Capri Room | Sydney |
06:50~07:20 | Registration | Poster Exhibition |
|||
07:20~07:30 | Opening | ||||
07:30~08:30 | ¿¬±¸ºñ ¹× ÀåÇÐ±Ý º¸°í | ||||
08:30~10:00 | Á¤Ã¥°úÁ¦ ¹ßÇ¥ | ||||
10:00~10:30 | Coffee Break | ||||
10:30~12:00 | Plenary Session | ||||
12:00~12:20 | ÀÓ½ÃÃÑȸ | ||||
12:20~12:50 | Coffee Break | ||||
12:50~13:50 | Luncheon Symposium | ||||
13:50~14:00 | Coffee break | ||||
14:00~15:30 | Concurrent Symposium 2 (Liver) |
Concurrent Symposium 1 (Basic) |
Concurrent Symposium 3 (Thoracic) |
Concurrent Symposium 4 (Kidney) |
|
15:30~16:00 | Coffee break | ||||
16:00~17:30 | Concurrent Symposium 6 (Liver) |
Concurrent Symposium 5 (Organ Donation) |
Concurrent Symposium 7 (Coordinator) |
Concurrent Symposium 8 (Kidney) |
|
17:30 | Closing |
³»¿ë | ÁÂÀå/¿¬ÀÚ | |
06:50~07:20 | Registration | |
07:20~07:30 | Opening | ±èµ¿±¸(°¡Å縯ÀÇ´ë, ´ëÇÑÀ̽ÄÇÐȸ ȸÀå) |
07:30~08:30 | ¿¬±¸ºñ ¹× ÀåÇÐ±Ý º¸°í |
ÁÂÀå: Á¤ÁØÇå(ÇѼº´¿ø) À¯Èñö(ÀüºÏÀÇ´ë) |
07:30~07:50 | Outcomes After steatotic Liver Transplantation | Á¶À翵(¼¿ïÀÇ´ë) |
07:50~08:10 | Transplantation for hilar cholangiocarcinoma | ±è¹ü¼ö(°æÈñÀÇ´ë) |
08:10~08:30 | Primate Allo-islet Transplantation Modeling | ¹ÚÀç¹ü(¼º±Õ°üÀÇ´ë) |
08:30~10:00 | Á¤Ã¥°úÁ¦ º¸°í | ÁÂÀå: ±èµ¿±¸(°¡Å縯ÀÇ´ë) ÇÑ´öÁ¾(¿ï»êÀÇ´ë) |
08:30~08:50 | ½ÅÀå ¹× °£À̽Ŀ¡¼ Ç×ü¸Å°³ °ÅºÎ¹ÝÀÀÀÇ ÀÓ»ó-º´¸®ÇÐÀû Ư¡ | Á¤ÇöÁÖ(¿¬¼¼ÀÇ´ë) |
08:50~09:10 | KOTRY °æ°ú º¸°í | ±è¸í¼ö(¿¬¼¼ÀÇ´ë) |
09:10~09:30 | KONOS 2014³âµµ º¸°í | ±èÅÃ(KONOS) |
09:30~09:45 | Çѱ¹Àå±â±âÁõ¿ø ¼º°úº¸°í | ÇÏÁ¾¿ø(KODA) |
09:45~10:00 | 2014 »ý¸íÀձ⠻ç¾÷ º¸°í | Á¶¿øÇö(»ý¸íÀÕ±â) |
10:00~10:30 | Coffee Break | |
10:30~12:00 | Plenary Session | ÁÂÀå: À̼®±¸(¼º±Õ°üÀÇ´ë) ±èÀ¯¼±(¿¬¼¼ÀÇ´ë) |
10:30~11:30 | Ethical considerations and outcomes for live kidney donors. | Peter Reese(University of Pennsylvania) |
11:30~12:00 | 3D printing : '3rd Industrial Revolution' and Translational Research" | ÀÌÁø¿ì(°¡Ãµ´ë) |
12:00~12:20 | ÀÓ½ÃÃÑȸ | |
12:20~12:50 | Coffee Break | |
12:50~13:50 | Luncheon Symposium 1(¾Æ½ºÅÚ¶ó½º) | ÁÂÀå: ¹Ú¼ö±æ(¿ï»êÀÇ´ë) ±è¸í¼ö(¿¬¼¼ÀÇ´ë) |
ADV in De-novo | Jeff Zaltzman(Nephrologist, Canada) | |
12:50~13:50 | Luncheon Symposium 2(Á¾±Ù´ç) | ÁÂÀå: ±èÀ¯¼±(¿¬¼¼ÀÇ´ë) ¹®Àμº(°¡Å縯ÀÇ´ë) |
Generic formulation of Tacrolimus, TacroBell®, in de novo kidney transplant recipients: six-year experience. | Çã¿ì¼º(¼º±Õ°üÀÇ´ë) | |
Experiences of Mizoribine (Bredinin®) as Antimetabolite for Kidney Transplantation (Single center experience) | ¿ÀÁؼ®(ºÀ»ýº´¿ø) | |
12:50~13:50 | Luncheon Symposium 3(³ì½ÊÀÚ) | ÁÂÀå: ¼°æ¼®(¼¿ïÀÇ´ë) Á¶Àç¿ø(¼º±Õ°üÀÇ´ë) |
The development of HBIG Gene might open new era for prophylaxis in HBV-infected liver transplant patioents | Á¤µ¿È¯(¿ï»êÀÇ´ë) | |
13:50~14:00 | Coffee Break | |
14:00~15:30 | Concurrent Symposium 1(Basic): New technology for transplantation | ÁÂÀå: Á¶È«·¡(¿ï»ê´ëº´¿ø) ¾çö¿ì(°¡Å縯ÀÇ´ë) |
14:00~14:30 | Blastocyst complementation: Towards compensation of organogenesis using pluripotent stem cells | ½ÉÈ£¼·(´Ü±¹ÀÇ´ë) |
14:30~15:00 | Xenotransplantation | ¾È±Ô¸®(¼¿ïÀÇ´ë) |
15:00~15:30 | Antibody drug conjugate (ADC) for transplantation | Á¤ÁØÈ£(¼¿ïÀÇ´ë) |
14:00~15:30 | Concurrent Symposium 2(Liver): How to make safe living donation | ÁÂÀå: Á¶Àç¿ø(¼º±Õ°üÀÇ´ë) ¼°æ¼®(¼¿ïÀÇ´ë) |
14:00~14:30 | Donor evlaluation and graft type selesction to minimize the risk | ÁÖÁ¾¿ì(ºÎ»êÀÇ´ë) |
14:30~15:00 | Donor morbidity is real: How to prevent or manage to avoid long-lasting sequelae | Á¤µ¿È¯(¿ï»êÀÇ´ë) |
15:00~15:30 | Long-term follow-up protocols and outcomes in living liver donor | À̳²ÁØ(¼¿ïÀÇ´ë) |
14:00~15:30 | Concurrent Symposium 3(Thoracic): Primary graft failure after thoracic transplantation | ÁÂÀå: ¹éȿä(¿¬¼¼ÀÇ´ë) ±èÀçÁß(¿ï»êÀÇ´ë) |
14:00~14:22 | Organ preservation in heart transplantation | Á¤¼ºÈ£(¿ï»êÀÇ´ë) |
14:22~14:44 | Primary graft failure after heart transplantation | À±Á¾Âù(¿¬¼¼ÀÇ´ë) |
14:44~15:06 | Pathophysiology and risk factors of PGD in lung transplantation | ±è¼ÛÀÌ(¿¬¼¼ÀÇ´ë) |
15:06~15:28 | Management of PGD following lung transplantation | ±èµµÇü(ºÎ»êÀÇ´ë) |
14:00~15:30 | Concurrent Symposium 4(Kidney): Safety issues in living kidney donor | ÁÂÀå: ±èÁß°æ(ºÀ»ýº´¿ø) ±è¼ºÁÖ(¼º±Õ°üÀÇ´ë) |
14:00~14:22 | Donor selection | ÀÌÁ¾¼ö(¿ï»êÀÇ´ë) |
14:22~14:44 | Surgical issues in live donor nephrectomy | À±¿µÀº(¿¬¼¼ÀÇ´ë) |
14:44~15:06 | Characteristics and Outcomes of Living Kidney Donors | ¾çÀç¼®(¼¿ï´ëº´¿ø) |
15:06~15:28 | Panel discussion | ÀÌÁ¾¼ö, À±¿µÀº, ¾çÀç¼® |
15:30~16:00 | Coffee Break | |
16:00~17:30 | Concurrent Symposium 5(Organ Donation): Issues in organ donation | ÁÂÀå: Á¤»ó¿µ(Àü³²ÀÇ´ë) ±Ç¿ÀÁ¤(ÇѾçÀÇ´ë) |
16:00~16:22 | Donation improvement program | ÇÏÁ¾¿ø(¼¿ïÀÇ´ë) |
16:22~16:44 | School education program | ¿ÀÁöÀº(ÇѸ²ÀÇ´ë) |
16:44~17:06 | Kidney allocation rule | ±è¿µÈÆ(ÀÎÁ¦ÀÇ´ë) |
17:06~17:28 | Liver allocation rule | ±è¸í¼ö(¿¬¼¼ÀÇ´ë) |
16:00~17:30 | Concurrent Symposium 6(Liver): Is the long-term use of immunosuppresion an old
friend or old foe? |
ÁÂÀå:Ȳ ½Å(¿ï»êÀÇ´ë) À̱¤¿õ(¼¿ïÀÇ´ë) |
16:00~16:30 | The metabolic complication related with the long-term use of immunosuppression | À̽ÃÈÆ(°¡ÃµÀÇ´ë) |
16:30~17:00 | CNI-related renal dysfunction in long-term survivors after LT: How to expect and manage | ÁÖµ¿Áø(¿¬¼¼ÀÇ´ë) |
17:00~17:30 | Withdrawl or minimization of the immunosuppresion: Where are we? | ¼Û±â¿ø(¿ï»êÀÇ´ë) |
16:00~17:30 | Concurrent Symposium 7(Coordinator) | ÁÂÀå: Àü°æ¿Á(¼¼ºê¶õ½ºº´¿ø) °ÇöÁø(KODA) |
16:00~17:00 | ³ª´Â Àü¹®°¡Àΰ¡? | ¼Õ¼±¿µ(¼¼ºê¶õ½ºº´¿ø) |
17:00~17:30 | Àå±âÀ̽ļ¾ÅÍ ÄÚµð³×ÀÌÅÍÀÇ Àü¹®¼º | ±èÇü¼÷(¼¿ï¼º¸ðº´¿ø) |
16:00~17:30 | Concurrent Symposium 8(Kidney): Hot issues in post-transplant management | ÁÂÀå: ¹®Àμº(°¡Å縯ÀÇ´ë) ¹Ú¼º±¤(ÀüºÏÀÇ´ë) |
16:00~16:30 | How to manage multidrug-resistant bacterial organisms | ±è»óÀÏ(°¡Å縯ÀÇ´ë) |
16:30~17:00 | How to manage HCV - recipient preparatin and post-transplant management | ÀÓ¿µ¼®(¿ï»êÀÇ´ë) |
17:00~17:30 | How to treat recurrent focal segmental glomerulosclerosis(FSGS) and primary hyperoxaluria | ³ë ÇÑ(°¡ÃµÀÇ´ë) |
17:30~ | Closing |